Opinion|Videos|January 16, 2026
COMMANDS Post Hoc Analysis: Outcomes With First-Line Luspatercept in Lower-Risk MDS With Early Disease Characteristics
Author(s)Amer Zeidan, MBBS, MD
Amer Zeidan, MBBS, unpacks data from a post hoc analysis of the COMMANDS trial of luspatercept in lower-risk MDS.
Advertisement
Episodes in this series
Amer Zeidan, MBBS, unpacks results from a post hoc analysis of the phase 3 COMMANDS trial assessing luspatercept (Reblozyl) in patients with lower-risk myelodysplastic syndromes (MDS) and early disease characteristics. He highlights outcomes across relevant subgroups and discusses implications for patient selection. Zeidan explains how these findings may further refine first-line treatment strategies.
Advertisement
Related to this article
A pilot study represents a milestone toward testing a faster, more powerful, and potentially less-toxic form of radiation therapy for cancer treatment.
Oral azacitidine and cedazuridine met the end point of total cycle azacitidine exposure vs subcutaneous azacitidine in MDS or CMML.
UTRxMYCN M1-14 received orphan drug status for soft tissue sarcoma and RPDD for rhabdomyosarcoma.
Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.
Estelamari Rodriguez, MD, MPH, discusses the rationale, design, and practice implications of the phase 3 RELATIVITY-1093 trial in nonsquamous NSCLC.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
A New England Journal of Medicine report describes complete hepatoblastoma regression in a 3-year-old treated with a novel immunotherapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Plinabulin Plus Docetaxel in Post-ICI Non-Squamous NSCLC
2
Breast Cancer Experts Highlight Abstracts to Watch at ESMO 2026
3
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
4
Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape
5